Literature DB >> 26675404

Conjunctival fibrosis following filtering glaucoma surgery.

Günther Schlunck1, Tobias Meyer-ter-Vehn2, Thomas Klink2, Franz Grehn2.   

Abstract

Despite advances in surgical technique and postoperative care, fibrosis remains the major impediment to a marked reduction of intraocular pressure without the need of additional medication (complete success) following filtering glaucoma surgery. Several aspects specific to filtering surgery may contribute to enhanced fibrosis. Changes in conjunctival tissue structure and composition due to preceding treatments as well as alterations in interstitial fluid flow and content due to aqueous humor efflux may act as important drivers of fibrosis. In light of these pathophysiological considerations, current and possible future strategies to control fibrosis following filtering glaucoma surgery are discussed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Extracellular matrix; Fibrosis; Glaucoma; Mechanotransduction; Surgery; TGF-beta

Mesh:

Substances:

Year:  2016        PMID: 26675404     DOI: 10.1016/j.exer.2015.03.021

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  37 in total

Review 1.  [Revision after filtration surgery].

Authors:  A G M Jünemann; R Rejdak; B Hohberger
Journal:  Ophthalmologe       Date:  2016-11       Impact factor: 1.059

Review 2.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

3.  Comparison of conjunctival vascularity changes using optical coherence tomography angiography after trabeculectomy and phacotrabeculectomy.

Authors:  Je Hyun Seo; Young Lee; Jong Hoon Shin; Ye An Kim; Keun Heung Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-10       Impact factor: 3.117

4.  Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma.

Authors:  Sana' Muhsen; Javiera Compan; Tze Lai; Christoph Kranemann; Catherine Birt
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

5.  Five-year results of non-penetrating deep sclerectomy with demineralized cancellous bone xenogenically derived collagen glaucoma implant.

Authors:  Natalia S Anisimova; Lisa B Arbisser; Sergey I Anisimov; Lusine L Arutyunyan; Natalya F Shilova; Gilyana Bashaeva; Roman V Kirtaev; Svetlana Yu Anisimova
Journal:  Int Ophthalmol       Date:  2021-03-03       Impact factor: 2.031

Review 6.  The control of conjunctival fibrosis as a paradigm for the prevention of ocular fibrosis-related blindness. "Fibrosis has many friends".

Authors:  Peng Tee Khaw; Yann Bouremel; Stephen Brocchini; Christin Henein
Journal:  Eye (Lond)       Date:  2020-06-25       Impact factor: 3.775

7.  Functional evaluation of the filtering bleb by ultrasound biomicroscopy after trabeculectomy with mitomycin C.

Authors:  Ali Abbas El Salhy; Rabab Mohamed Elseht; Ahmed Fekry Al Maria; Saied Mohamed Abd El-Wahab Shalaby; Tarek Ragaee Hossein
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

8.  Triptolide inhibits TGF-β-induced matrix contraction and fibronectin production mediated by human Tenon fibroblasts.

Authors:  Yang Liu; Ping-Ping Liu; Lei Liu; Xiao-Shuo Zheng; Hui Zheng; Cheng-Cheng Yang; Ci-Ren Luobu; Ye Liu
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

9.  The myofibroblast, biological activities and roles in eye repair and fibrosis. A focus on healing mechanisms in avascular cornea.

Authors:  Maxime Rocher; Pierre-Yves Robert; Alexis Desmoulière
Journal:  Eye (Lond)       Date:  2019-11-25       Impact factor: 3.775

Review 10.  Standalone XEN45 Gel Stent implantation versus combined XEN45-phacoemulsification in the treatment of open angle glaucoma-a systematic review and meta-analysis.

Authors:  Sheng Yang Lim; Bjorn Kaijun Betzler; Leonard Wei Leon Yip; Syril Dorairaj; Bryan Chin Hou Ang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-29       Impact factor: 3.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.